| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 4.524 | 5.279 | 5.906 | 0 | 0 |
| Total Income - EUR | - | - | - | - | - | 4.793 | 5.279 | 5.906 | 0 | 0 |
| Total Expenses - EUR | - | - | - | - | - | 1.496 | 1.001 | 2.250 | 885 | 680 |
| Gross Profit/Loss - EUR | - | - | - | - | - | 3.297 | 4.278 | 3.656 | -885 | -680 |
| Net Profit/Loss - EUR | - | - | - | - | - | 3.169 | 4.123 | 3.488 | -885 | -680 |
| Employees | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Xela Pharm Consulting S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 870 | 634 | 418 | 199 | 0 |
| Current Assets | - | - | - | - | - | 2.409 | 6.696 | 10.679 | 10.028 | 9.972 |
| Inventories | - | - | - | - | - | 0 | 0 | 505 | 503 | 501 |
| Receivables | - | - | - | - | - | 101 | 0 | -351 | -350 | -348 |
| Cash | - | - | - | - | - | 2.308 | 6.696 | 10.525 | 9.875 | 9.819 |
| Shareholders Funds | - | - | - | - | - | 3.199 | 7.250 | 10.760 | 9.842 | 9.107 |
| Social Capital | - | - | - | - | - | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | 81 | 79 | 336 | 385 | 865 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7490 - 7490" | |||||||||
| CAEN Financial Year |
7490
|
|||||||||
Comments - Xela Pharm Consulting S.r.l.